Prednisone for Decompensated Congestive Heart Failure
We designed this, randomized, double-blind, placebo-controlled trial to determine the clinical efficacy of chronic administration of prednisone on renal function and clinical status when added to standard care.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Chronic Administration of Prednisone in Management of Patients With Decompensated Congestive Heart Failure|
- Change from baseline in serum creatinine level, Patient and physician-assessed symptom scales at day 1, day 3, the end of week 1 and week 2
- Daily urine volume, changes in body weight, serum electrolyte levels at the end of week 1, week 2, respectively, and overall safety profile
|Study Start Date:||October 2006|
|Estimated Study Completion Date:||July 2008|
Studies showed that glucocorticoids could specifically dilate renal vessel, increase in GFR, and regulate synthesis and release of atrial natriuretic peptide (ANP), upregulate ANP receptors on vascular endothelial cells, leading to significant diuresis and natriuresis. Adding glucocorticoids to standard care may potentiate the diuretic and natriuretic effects of diuretics and improve renal function, thus improve the clinical outcomes.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00369044
|The First Hospital of Hebei Medical University|
|Shijiazhuang, Hebei, China, 050031|
|Principal Investigator:||Kunshen Liu, MD||Hebei Medical University First Hospital|